6,578 Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Westpac Banking Corp

Westpac Banking Corp increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 93.2% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,637 shares of the biopharmaceutical company’s stock after acquiring an additional 6,578 shares during the period. Regeneron Pharmaceuticals comprises approximately 0.6% of Westpac Banking Corp’s holdings, making the stock its 26th largest holding. Westpac Banking Corp’s holdings in Regeneron Pharmaceuticals were worth $10,341,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Berger Financial Group Inc bought a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at $228,000. Ieq Capital LLC boosted its stake in Regeneron Pharmaceuticals by 32.0% in the third quarter. Ieq Capital LLC now owns 63,500 shares of the biopharmaceutical company’s stock worth $48,150,000 after purchasing an additional 15,395 shares in the last quarter. Focus Advisor Solutions LLC boosted its stake in Regeneron Pharmaceuticals by 287.9% in the third quarter. Focus Advisor Solutions LLC now owns 8,397 shares of the biopharmaceutical company’s stock worth $6,367,000 after purchasing an additional 6,232 shares in the last quarter. Checchi Capital Advisers LLC boosted its stake in Regeneron Pharmaceuticals by 20.4% in the third quarter. Checchi Capital Advisers LLC now owns 550 shares of the biopharmaceutical company’s stock worth $417,000 after purchasing an additional 93 shares in the last quarter. Finally, Independent Advisor Alliance grew its holdings in shares of Regeneron Pharmaceuticals by 10.1% during the third quarter. Independent Advisor Alliance now owns 829 shares of the biopharmaceutical company’s stock worth $629,000 after purchasing an additional 76 shares during the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, Director Christine A. Poon sold 7,830 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $969.09, for a total value of $7,587,974.70. Following the completion of the sale, the director directly owned 5,219 shares in the company, valued at $5,057,680.71. This trade represents a 60.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Huda Y. Zoghbi sold 7,439 shares of the business’s stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $970.46, for a total value of $7,219,251.94. Following the sale, the director directly owned 1,703 shares of the company’s stock, valued at $1,652,693.38. This represents a 81.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 32,039 shares of company stock valued at $29,825,285 over the last ninety days. Company insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals News Summary

Investors following REGN have been watching these news items:

  • Positive Sentiment: The FDA approved Livsayis (cemdisiran) for adults with anti-AChR-positive generalized myasthenia gravis. It is the first approved siRNA therapy for the disease and the only treatment described as requiring just four subcutaneous doses per year. Approval was based on Phase 3 results showing sustained disease control. Livsayis is Regeneron’s first marketed RNAi drug and its first neurology medicine. Reuters article
  • Positive Sentiment: The European Commission approved more flexible Libtayo dosing across six cancer indications. Less frequent infusions and shorter administration times could improve convenience and support use of Regeneron’s oncology drug. Libtayo dosing article
  • Negative Sentiment: Livsayis will enter a market with established treatments from AstraZeneca and Argenx, so commercial uptake and competition will influence how much the approval adds to Regeneron’s results. Market competition article

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $923.34 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.35 and a quick ratio of 2.89. The company has a 50 day moving average price of $826.97 and a 200 day moving average price of $751.27. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $591.52 and a fifty-two week high of $991.73. The stock has a market capitalization of $95.52 billion, a PE ratio of 20.39, a price-to-earnings-growth ratio of 1.25 and a beta of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last announced its quarterly earnings data on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, beating analysts’ consensus estimates of $16.51 by $3.56. The firm had revenue of $5.12 billion for the quarter, compared to analyst estimates of $4.58 billion. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The business’s quarterly revenue was up 36.3% compared to the same quarter last year. During the same period last year, the company earned $11.83 EPS. Analysts forecast that Regeneron Pharmaceuticals, Inc. will post 58.26 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 3rd. Stockholders of record on Friday, November 20th will be given a dividend of $0.94 per share. The ex-dividend date is Friday, November 20th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. Regeneron Pharmaceuticals’s payout ratio is presently 8.30%.

Analysts Set New Price Targets

Several analysts have recently commented on REGN shares. Canaccord Genuity Group raised their target price on Regeneron Pharmaceuticals from $875.00 to $922.00 and gave the company a “buy” rating in a research note on Wednesday, October 28th. UBS Group raised Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their price target for the company from $660.00 to $978.00 in a report on Thursday, October 15th. Bank of America upped their price target on shares of Regeneron Pharmaceuticals from $908.00 to $1,030.00 and gave the stock a “buy” rating in a research report on Monday, November 2nd. Wall Street Zen raised shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Sunday, September 20th. Finally, Cantor Fitzgerald increased their price objective on shares of Regeneron Pharmaceuticals from $795.00 to $980.00 and gave the stock an “overweight” rating in a report on Monday, November 2nd. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $904.41.

Get Our Latest Stock Report on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Profile

(Free Report)

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions. The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.

Featured Articles

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.